Kedrion S.p.A.
11
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 20/100
9.1%
1 terminated/withdrawn out of 11 trials
80.0%
-6.5% vs industry average
82%
9 trials in Phase 3/4
100%
4 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
Role: lead
A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome
Role: lead
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Role: lead
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Role: lead
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Role: lead
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
Role: lead
Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients
Role: lead
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
Role: lead
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
Role: lead
Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
Role: collaborator
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
Role: lead
All 11 trials loaded